Mesoblast (NASDAQ:MESO) Upgraded at Maxim Group

Maxim Group upgraded shares of Mesoblast (NASDAQ:MESO) from a hold rating to a buy rating in a research note published on Tuesday morning, MarketBeat.com reports. Maxim Group currently has $12.00 price target on the stock.

MESO has been the subject of several other reports. Jefferies Financial Group raised Mesoblast from a hold rating to a buy rating in a report on Thursday, August 29th. Cantor Fitzgerald reissued an overweight rating on shares of Mesoblast in a research report on Thursday, August 29th. StockNews.com cut shares of Mesoblast from a hold rating to a sell rating in a report on Wednesday, September 4th. Finally, Piper Sandler raised Mesoblast from a neutral rating to an overweight rating and raised their price target for the stock from $4.00 to $11.00 in a report on Tuesday, July 23rd. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to MarketBeat, Mesoblast has a consensus rating of Moderate Buy and an average price target of $11.50.

Mesoblast Stock Up 2.4 %

Shares of NASDAQ MESO opened at $7.60 on Tuesday. The business has a 50-day moving average price of $6.60 and a 200 day moving average price of $6.44. The stock has a market cap of $867.75 million, a PE ratio of -6.79 and a beta of 3.47. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.21. Mesoblast has a 52-week low of $1.61 and a 52-week high of $8.66.

Hedge Funds Weigh In On Mesoblast

A number of large investors have recently bought and sold shares of MESO. GAMMA Investing LLC increased its stake in shares of Mesoblast by 50.1% during the second quarter. GAMMA Investing LLC now owns 4,981 shares of the company’s stock worth $34,000 after acquiring an additional 1,663 shares during the period. Perkins Coie Trust Co purchased a new stake in Mesoblast in the 2nd quarter valued at approximately $68,000. Pine Valley Investments Ltd Liability Co acquired a new position in Mesoblast during the 2nd quarter worth approximately $80,000. Rathbones Group PLC purchased a new position in shares of Mesoblast during the 2nd quarter worth approximately $95,000. Finally, Chapin Davis Inc. lifted its holdings in shares of Mesoblast by 50.0% in the 2nd quarter. Chapin Davis Inc. now owns 15,000 shares of the company’s stock valued at $102,000 after buying an additional 5,000 shares during the period. Hedge funds and other institutional investors own 1.43% of the company’s stock.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.